COVID-19 Critical Intelligence Unit

## **Evidence digest**

17 June 2022

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

# Telerehabilitation post-discharge, effects of previous infection & vaccination on Omicron infection, research questions on long COVID

#### Peer reviewed journals featured:

- Systematic reviews on:
  - o Remdesivir in treating COVID-19 inpatients receiving supplemental oxygen here
  - Multiple sclerosis disease-modifying therapies and COVID-19 vaccines <u>here</u>
- Randomised trials of:
  - A telerehabilitation program in post-discharge COVID-19 patients (TERECO) here
  - Vaxzevria (AstraZeneca) vaccine in children and adolescents aged 6–17 years here
  - Text messaging and behavioural interventions supporting COVID-19 vaccination here
- A narrative review on COVID-19 and liver disease here
- Observational studies on:
  - o Effects of previous infection and vaccination on symptomatic Omicron infections here
  - Immune boosting by Omicron and previous SARS-CoV-2 exposure here
  - o Risk of myocarditis and pericarditis after mRNA vaccination in the US here
  - o Change in COVID-19 risk over time following vaccination with CoronaVac here
  - COVID-19 trajectories among 57 million adults in England <u>here</u>
  - Efficacy and safety of COVID-19 revaccination in non-responders with immunemediated inflammatory disease <u>here</u>
  - o Comirnaty (Pfizer) vaccine and booster in autoimmune rheumatic disease patients here
  - Sociodemographic inequality in COVID-19 vaccination uptake in England <u>here</u> and in COVID-19 burden in Israel <u>here</u>
  - o "Long COVID" results after hospitalisation for SARS-CoV-2 infection here
  - o Waning effectiveness of the third dose of Comirnaty (Pfizer) vaccine here
  - o Prevalence of SARS-CoV-2 positivity in infants with bronchiolitis here
  - o Selective visuoconstructional impairment following mild COVID-19 here
- An international Delphi consensus study on core outcomes for post-COVID-19 condition in adults for use in clinical practice and research <u>here</u>
- Commentary on 10 key research questions regarding the long-term sequelae of COVID-19 here
- An editorial on comorbidities and COVID-19 here



#### Letters and correspondence discussed:

- Neutralisation of Omicron BA.4/5 and BA.2.12.1 subvariants <u>here</u>
- Neutralisation of Deltacron and BA.3 variants <u>here</u>
- The seroprevalence of SARS-CoV-2-specific antibodies in children in Australia here
- Oral antiviral treatment in patients with systemic rheumatic disease at risk of severe COVID-19 here
- Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations <u>here</u>

#### Pre-peer review articles featured:

Neutralization of Omicron sublineages and Deltacron by 3 doses of Comirnaty (Pfizer) or BA.1 infection <u>here</u>

#### **Guidance and reports**

- The World Health Organization published:
  - o Updates of its COVID-19 epidemiological report here
  - Guidance on integrated sentinel surveillance of influenza and SARS-CoV-2 using the Global Influenza Surveillance and Response System Plus <u>here</u>
  - A report on disease severity associated with Omicron compared with Delta in hospitalised patients with suspected or confirmed SARS-CoV-2 infection <u>here</u>
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts <u>here</u>

### News and blogs

- UK patients without respiratory symptoms no longer need to wear a face mask in GP surgeries here
- Unusable PPE worth £4bn will be burned here
- New COVID-19 drugs face delays as trials grow more difficult <u>here</u>
- COVID-19 and smell loss <u>here</u> and <u>here</u>
- Omicron infection is poor booster to immunity <u>here</u>

<u>Click here</u> to subscribe to, or unsubscribe from, the evidence digest.

#### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on <u>COVID-19 transmission</u>, SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of</u> <u>COVID-19 (long COVID)</u>, <u>surgery and COVID-19</u>, and <u>rapid testing</u>.



The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.